NARA Discovery
Article Details
← Back to Search Results
Journal Article

Changes in the Fraction Metabolized in Children Younger than Four Years; When is Clearance Scaling for the Dominant Elimination Route in Adults Appropriate?

Anne van Rongen; Robbin Grijseels; Elisa A. M. Calvier; Karel Allegaert; Catherijne A. J. Knibbe; Elke H. J. Krekels
Pharmaceutical Research · Vol. 42, Issue 10 · pp. 1691-1700 · 2025

Abstract

Introduction A common approach to scaling clearance from adults to children is to apply a maturation function for the dominant elimination pathway in adults. We investigate for drugs mainly cleared through hepatic metabolism, how the fraction metabolized changes and whether this pathway remains dominant in young children. Methods A physiologically-based pharmacokinetic workflow was developed investigating 460 hypothetical drugs that were for 90% or 70% cleared through hepatic metabolism in adults with remaining clearance through glomerular filtration. Their unbound drug fractions were between 1 and 99% and they were metabolized by isoenzymes with different maturation patterns. Absolute and relative clearance through hepatic metabolism was calculated in a typical adult and seven typical pediatric individuals younger than 4 years. Results When hepatic metabolism comprises 90% of total plasma clearance in adults, it tends to remain the dominant elimination route throughout childhood for substrates of all isoenzymes, except for substrates of CYP2A6, UGT1A1, and UGT2B7. However, when hepatic metabolism comprises 70% of the total plasma clearance in adults, hepatic metabolism will not remain dominant for at least part of the pediatric age-range for substrates of many enzymes, except for substrates of CYP2C8, CYP2C9, and SULT1A1. Conclusion This study identified scenarios in which hepatic metabolism cannot be assumed to remain dominant in children younger than 4 years, when it is the dominant elimination route in adults. In these scenarios, scaling for the dominant clearance route in adults will yield underprediction of total plasma clearance and the contribution of alternative routes needs to be considered.

Bibliographic Information

JournalPharmaceutical Research
PublisherSpringer
Publication Date2025-10-01
Publication Year2025
Volume42
Issue10
Pages1691-1700
Document TypeJournal Article
Print ISSN0724-8741
eISSN1573-904X
DOI10.1007/s11095-025-03948-7

Access Information

NARA Access Coverage1984-01-01~Current
Journal Homepagehttps://www.springer.com/journal/11095
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.